- Home
- SLGL vs VYNE Comparison
SLGL vs VYNE Comparison
Compare SLGL & VYNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLGL
- VYNE
- Stock Information
- Founded
- SLGL 1997
- VYNE 2003
- Country
- SLGL Israel
- VYNE United States
- Employees
- SLGL N/A
- VYNE N/A
- Industry
- SLGL Biotechnology: Pharmaceutical Preparations
- VYNE Biotechnology: Pharmaceutical Preparations
- Sector
- SLGL Health Care
- VYNE Health Care
- Exchange
- SLGL Nasdaq
- VYNE Nasdaq
- Market Cap
- SLGL 19.3M
- VYNE 16.0M
- IPO Year
- SLGL 2018
- VYNE 2018
- Fundamental
- Price
- SLGL $7.26
- VYNE $1.42
- Analyst Decision
- SLGL Buy
- VYNE Strong Buy
- Analyst Count
- SLGL 1
- VYNE 2
- Target Price
- SLGL $40.00
- VYNE $6.25
- AVG Volume (30 Days)
- SLGL 25.3K
- VYNE 964.9K
- Earning Date
- SLGL 08-15-2025
- VYNE 08-13-2025
- Dividend Yield
- SLGL N/A
- VYNE N/A
- EPS Growth
- SLGL N/A
- VYNE N/A
- EPS
- SLGL N/A
- VYNE N/A
- Revenue
- SLGL $12,103,000.00
- VYNE $605,000.00
- Revenue This Year
- SLGL N/A
- VYNE $42.51
- Revenue Next Year
- SLGL $31.17
- VYNE N/A
- P/E Ratio
- SLGL N/A
- VYNE N/A
- Revenue Growth
- SLGL 603.66
- VYNE 43.03
- 52 Week Low
- SLGL $3.34
- VYNE $0.85
- 52 Week High
- SLGL $16.50
- VYNE $4.30
- Technical
- Relative Strength Index (RSI)
- SLGL 52.97
- VYNE 77.62
- Support Level
- SLGL $7.02
- VYNE $0.85
- Resistance Level
- SLGL $7.58
- VYNE $0.97
- Average True Range (ATR)
- SLGL 0.37
- VYNE 0.13
- MACD
- SLGL 0.02
- VYNE 0.08
- Stochastic Oscillator
- SLGL 41.28
- VYNE 85.56
About SLGL Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.
About VYNE VYNE Therapeutics Inc.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.